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Abstract 
A multi-drug resistant strain of E. miricola was isolated from the urine of a 2-year old boy 
hospitalized for severe clinical conditions. The strain produces two metallo-β-lactamases belonging 
to subclasses B1 and B3:  a new BlaB variant (BlaB-15) and a GOB-7-like enzyme.  
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Genus Elizabethkingia (formerly Chryseobacterium) belongs to Flavobacteriaceae family and 
includes two main species, Elizabethkingia meningoseptica and Elizabethkingia miricola, which are 
genetically different from other Elizabethkingia species, as revealed by 16S rRNA gene sequence 
studies (Kim et al., 2005). These bacteria are ubiquitous in natural (freshwater, saltwater and soil) 
and hospital environments. E. meningoseptica is an important emerging pathogen responsible for 
severe healthcare infections (Jean et al., 2014). In clinical settings, Elizabethkingia species have 
been described as etiological agents of meningitis, especially in premature infants, sepsis, 
bacteremia, pneumonia and endocarditis (Jean et al., 2014; de Silva et al., 2013). Carbapenem 
resistance in E. meningoseptica is mainly due to the production of metallo-β-lactamases (MBLs) as 
GOB and BlaB variants (Bellais et al., 2000; Gonzales and Vila, 2012).  
E. miricola was isolated for the first time in 2003 from the condensation water on the space station 
Mir (Li et al., 2003). The first case of infection due to E. miricola (pneumonia and sepsis) was 
described in 2008 in a man with lymphoma and under mechanical ventilator support (Green et al., 
2008). In the present study we identified a new BlaB variant (BlaB-15) from E. miricola isolated 
from a children with a complicated clinical condition. In September 2012, a 2-year old boy was 
admitted to the pediatric Emergency Department of the Children Bern University Hospital with 
fever and severe clinical conditions due to his underlying diseases (i.e., spina bifida, bladder 
exstrophy, atelectasis, tracheostomy, chronic kidney insufficiency, and Mitrofanoff stoma fistula). 
Urine was collected from an intermittent urinary catheter and showed leucocyte count of 500 
cells/μl and presence of nitrites. In addition, the urine sample gave the following results: 10.000 
CFU/ml of Klebsiella pneumoniae (ESBL-positive), 10.000 CFU/ml of E. miricola, 100.000 
CFU/ml of Pseudomonas aeruginosa, 100 CFU/ml of Candida and 100 CFU/ml of viridans 
streptococci. The young patient was under long-term treatment with nitrofurantoin. 
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The aim of this study was to characterize the BlaB-15 enzyme and to evaluate its contribution to 
resistance phenotype. E. miricola strain SW-2 was identified by using MALDI TOF MS system 
(Bruker Daltonik, Germany). Antimicrobial susceptibility test was performed by microdilution in 
cation-adjusted Mueller–Hinton broth (BBL, Becton Dickinson) using Sensititre ESB1F plates and 
GNX2F (TREK Diagnostic Systems, West Sussex, UK). Susceptibility results were interpreted 
according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
criteria set for Pseudomonas spp. (Eucast, 2015). As shown in Table 1, E. miricola SW-2 exhibits 
high MIC values for a large panel of antimicrobials including all cephalosporins, aztreonam, 
carbapenems, aminoglycosides, fluoroquinolones and polymyxins. 
Genomic DNA of E. miricola SW-2 was extracted according to standard procedure (Sambrook et 
al., 1989). The presence of large plasmid was also ascertained using Kado method (Kado and Liu, 
1981), but no plasmid bands were observed in E. miricola SW2. PCR screening was performed 
using specific primers to identify blaKPC, blaVIM, blaIMP, blaNDM-1, blaTEM, blaSHV, blaCTX-M 
determinants as previously reported (Perilli et al., 2013); the presence of blaB and blaGOB genes was 
explored by using the following primers: BlaB-for 
5’GGGGCATATGTTGAAAAGATTAAAAGGATTATT, BlaB-rev 
5’GGGGGATCCTTAATTTGAAGCCTTTTGTTTTGTTG, BlaGOB-for 
5’ATGAGAAATTTTGCTACACTG and BlaGOB-rev 5’TCGAACTGACTTGCATG. Two 
amplicons of 747 bp and 825 bp were amplified by BlaB-for/BlaB-rev and BlaGOB-for/BlaGOB-
rev primers, respsctively. The purified fragments were sequenced on both strands using a BigDye 
Sequencing Reaction Kit and an ABI PRISM1 310 Capillary Automated Sequencer (Life 
Technologies, Monza, Italy).  
Nucleotide sequences revealed that amplicons of 747 bp and 825 bp encoded for blaB-like and 
blaGOB-like metallo-β-lactamases (MBLs), respectively. The amplicon of 747 bp, encoding for an 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
open reading frame of 249 amino acids, had more than 90% amino acid identity with BlaB variant. 
However, some changes in the amino acid sequence make the present BlaB enzyme as new variant, 
named BlaB-15 (GenBank accession number KR054962). The figure 1 illustrates the comparison of 
BlaB-15 with other BlaB-variants with which our enzyme shows an higher similarity score (BlaB, 
BlaB-5, BlaB-7 and BlaB-8). BlaB-15 shows 18 different amino acids in the mature enzyme and 8 
different residues in signal peptide. The gene blaGOB-like of 825 bp encodes for a protein of 280 
amino acids that lacks the C-terminal portion. In figure 2 our GOB enzyme was compared with 
GOB-1 and GOB-7 variants. Compared to GOB-1, GOB-like shows 19 different residues in the 
mature enzyme. Despite of GOB-7, the enzyme produced by E. miricola SW2 showed an unusual 
residue of valine at position 258 (BBL B3 classification). Among GOB MBLs 
(http://www.ncbi.nlm.nih.gov), the position 258 is usually occupied by a leucine (GOB-1, -3, -4, -5, 
-6, -12, -13) or isoleucine (GOB-8, -9, -10, -18) residues (Bellais et al., 2000). However, the 
blaGOB-like gene found in E. miricola was not cloned and GOB-like enzyme was not characterized 
because it lacks in C-terminal region. 
The blaB-15 gene was cloned into pET-24(a) vector using NdeI and BamHI restriction sites to 
obtain the recombinant plasmid pET-BlaB-15 that was inserted by transformation in E. coli 
BL21(DE3) competent cells. The authenticity of recombinant plasmid was verified by DNA 
sequencing. The contribution of BlaB-15 to resistance phenotype was investigated versus a large 
panel of β-lactams by Minimal Inhibitory Concentration (MIC) experiments using E. coli 
BL21(DE3)/pET-BlaB-15. The antimicrobial susceptibility test was performed by conventional 
microdilution broth procedure, using a bacterial inoculum of 5 x 10
5
 CFU/ml as recommended by 
CLSI (CLSI, 2006). As shown in table 1, BlaB-15 confers resistance to penicillins-β-lactamase 
inhibitors combinations, cefotaxime, cefoxitin and carbapenems. Comparing MIC values with that 
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reported by BlaB prototype (Bellais et al., 2000), BlaB-15 seems to confer a broader resistance 
phenotype against cephalosporins. 
In this study, we described the simultaneous presence in E. miricola of BlaB-15, a new BlaB variant 
belonging to subclass B1 MBL, and GOB-7-like enzyme belonging to subclass B3 MBL. To date, 
BlaB and GOB MBLs were mainly found in E. menungosepticum (Bellais et al., 2000). To our 
knowledge, this is the first finding of metallo-β-lactamases in E. miricola clinical strains. 
Additionally, the 2-year old baby was also colonized by an ESBL-producing K. pneumoniae. The 
co-colonization/infection of a patient with different strains producing several β-lactamases 
complicates treatment.  
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 Legend to the figures  
Figure 1 
The MBL BlaB-15 amino acid sequence (GenBank accession number KR054962) was 
compared with BlaB prototype (GenBank accession number O08498), BlaB-5 (GenBank 
accession number Q9KJA9), BlaB-7 (GenBank accession number Q9KJA8) and BlaB-8 
(GenBank accession number Q9KJA7). Dashed lines indicate identical amino acid. The residues 
of BlaB-5, BlaB-7, BlaB-8 and BlaB-14 that differs from BlaB are also indicated. Arrow 
indicate the first residue of N-terminal region. In bold is indicated the sequence of BlaB-15 
enzyme found in E. miricola (this study). The catalytic residues including Zn1 ligand (H116, 
H118, H196) and Zn2 ligand (D120, C221, H263) are in bold underlined. 
 
Figure 2 
The GOB-like was compared with GOB-1 (AF090141) and GOB-7 (AF189297). Dashed lines 
indicate identical amino acids. In bold is indicated the sequence of GOB-like enzyme found in 
E. miricola (this study). The residues of GOB-7 and GOB-like that differs from GOB-1 are also 
indicated.The box shows the unique different residue between GOB-7 and GOB-like.  
 
Figure 1: Amino acid comparison of the BlaB-15 MBL with other BlaB, BlaB-5, BlaB-7 and BlaB-
8 variants 
 
BlaB            MLKKIKISLILALGLTSLQAFGQENPDVKIEKLKDNLYVYTTYNTFNGTKYAANAVYLVT 
blaB-5          ---RL-GL-V----F-G-Q----Q---I------------------K----------M-- 
blaB-7          -M-GL-GL-V----F-G-Q----Q---I------------------K----------M-- 
blaB-8          -M-GL-GL-V----F-G-QV---Q---I------------------K----------M-- 
blaB-15         ---RL-GL-V----F-G-QV---Q---I------------------K----------M-- 
                 :* :*  *:****:*.**.***:***:******************:**********:** 
 
BlaB            DKGVVVIDCPWGEDKFKSFTDEIYKKHGKKVIMNIATHSHDDRAGGLEYFGKIGAKTYST 
blaB-5          --------S-------------------------------------------L------- 
blaB-7          ---I----S-------------------------------------------L------- 
blaB-8          --------S-------------------------------------------L------- 
blaB-15         --------S-------------------------------------------L------- 
                ***:****.*******************************************:******* 
 
BlaB            KMTDSILAKENKPRAQYTFDNNKSFKVGKSEFQVYYPGKGHTADNVVVWFPKEKVLVGGC 
blaB-5          ---------------K------------NT----------------------D------- 
blaB-7          ---------------K-------------T----------------------D------- 
blaB-8          ---------------K-------------T----------------------D------- 
blaB-15         ---------------K-------------T----------------------D------- 
                ***************:************::**********************:******* 
 
BlaB            IIKSADSKDLGYIGEAYVNDWTQSVHNIQQKFSGAQYVVAGHDDWKDQRSIQHTLDLINE 
blaB-5          -V--G-------------------I-------PDV-------------T---------SD 
blaB-7          -V--G------F------------I-------PDV-------------T---------S- 
blaB-8          -V--G------F------------I-------PDV-------------T---------S- 
blaB-15         -V--G-------------------I-------PDV-------------T---------SD 
                *:**.******:************:*******...************* *********.: 
 
BlaB            YQQKQKASN 
blaB-5          --------- 
blaB-7          --------- 
blaB-8          --------- 
blaB-15         --------- 
                ********* 
 
 
Figure 1
Figure 2: Amino acid comparison of the GOB-like with GOB-1 and GOB-7 variants 
 
GOB-1           MRNFATLFFMFICLGLNAQVVKEPENMPKEWNQTYEPFRIAGNLYYVGTYDLASYLIVTD 
GOB-7                                --------------------------------------- 
GOB-like        ---------LLV--S--------------------------------------------- 
 
 
GOB-1           KGNILINTGTAESLPIIKANIQKLGFNYKDIKILLLTQAHYDHTGALQDLKTETGAKFYA 
GOB-7           -------------F----G------------------------------F---------- 
GOB-like        -------------F----G------------------------------F---------- 
                 
 
GOB-1           DKADADVLRTGGKSDYEMGKYGVTFKPVTPDKTLKDQDKITLGNTILTLLHHPGHTKGSC 
GOB-7           -----------------L---------------------------T-------------- 
GOB-like        -----------------L---------------------------T-------------- 
                 
 
GOB-1           SFIFETKDEKRKYRVLIANMPSVIVDKKFSEVTAYPNIQSDYAYTFKAMKNLDFDLWVAS 
GOB-7           ---------N---KI-------I-------------G------------------I---- 
GOB-like        ---------N---KI-------I-------------G------------------V---- 
 
GOB-1           HASQFDLHEKRKEGDPYNPQLFMDKQSYFQNLNDLEKSYLDKIKKDSQDK 
GOB-7           --------T------S---------EN--KRLE 
GOB-like        --------T------S---------EN--KRLE 
                 
 
Figure 2
Table 1: Antimicrobial susceptibility pattern of E. miricola SW2 and E. coli BL21(DE3)/pET-
BLAB-15 
 
 
§
Antimicrobial susceptibility tests were performed by microdilution in cation-adjusted Mueller–
Hinton broth (BBL, Becton Dickinson) using Sensititre ESB1F plates and GNX2F 
*
The antimicrobial susceptibility test was performed by the conventional microdilution broth 
procedure, using a bacterial inoculum of 5 x 10
5
 CFU/ml as recommended by CLSI (CLSI, 2006). 
MIC values are expressed in μg/ml. 
 
Antibiotic  E. miricola SW2
§
 
E. coli BL21(DE3) 
pET-BLAB-15
*
 
E. coli BL21(DE3)
* 
 
Piperacillin-tazobactam  8 >64 0.25 
Ticarcillin-clavulanate  ≥256 >64 0.25 
Cefoxitin  64 16 0.12 
Ceftriaxone  64 4 0.12 
Cefotaxime  32 16 0.50 
Ceftazidime  128 2 0.12 
Cefepime  16 0.50 0.06 
Aztreonam  ≥32 0.12 0.06 
Imipenem  ≥32 16 0.12 
Meropenem  ≥16 16 0.12 
Ertapenem  ≥8 8 0.12 
Gentamicin  <0.5 - - 
Tobramycin  ≥16 - - 
Amikacin  ≤2 - - 
Ciprofloxacin  0.50 - - 
Levofloxacin  <0.50 - - 
Trimethoprim/sulfamethoxazole  4 - - 
Colistin  ≥8 - - 
Polymixin B  ≥8 - - 
Doxycycline  ≤1 - - 
Minocycline  ≤1 - - 
Tigecycline  0.50 - - 
Table
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Abstract 
A multi-drug resistant strain of E. miricola was isolated from the urine of a 2-year old boy 
hospitalized for severe clinical conditions. The strain produces two metallo-β-lactamases belonging 
to subclasses B1 and B3:  a new BlaB variant (BlaB-15) and a GOB-7-like enzyme.  
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Genus Elizabethkingia (formerly Chryseobacterium) belongs to Flavobacteriaceae family and 
includes two main species, Elizabethkingia meningoseptica and Elizabethkingia miricola, which are 
genetically different from other Elizabethkingia species, as revealed by 16S rRNA gene sequence 
studies (Kim et al., 2005). These bacteria are ubiquitous in natural (freshwater, saltwater and soil) 
and hospital environments. E. meningoseptica is an important emerging pathogen responsible for 
severe healthcare infections (Jean et al., 2014). In clinical settings, Elizabethkingia species have 
been described as etiological agents of meningitis, especially in premature infants, sepsis, 
bacteremia, pneumonia and endocarditis (Jean et al., 2014; de Silva et al., 2013). Carbapenems 
resistance in E. meningoseptica is mainly due to the production of metallo-β-lactamases (MBLs) as 
GOB and BlaB variants (Bellais et al., 2000; Gonzales and Vila, 2012).  
E. miricola was isolated for the first time in 2003 from the condensation water on the space station 
Mir (Li et al., 2003). The first case of infection due to E. miricola (pneumonia and sepsis) was 
described in 2008 in a man with lymphoma and under mechanical ventilator support (Green et al., 
2008). In the present study we identified a new BlaB variant (BlaB-15) from E. miricola isolated 
from a children with a complicated clinical conditionsituation. In September 2012, a 2-year old boy 
was admitted to the pediatric Emergency Department of the Children Bern University Hospital with 
fever and severe clinical conditions due to his underlying diseases (i.e., spina bifida, bladder 
exstrophy, atelectasis, tracheostomy, chronic kidney insufficiency, and Mitrofanoff stoma fistula). 
Urine was collected from an intermittent urinary catheter and showed leucocyte count of 500 
leucocells/μul and presence of nitrites. In addition, the urine sample gave the following results: 
10.000 CFU/ml of Klebsiella pneumoniae (ESBL-positive), 10.000 CFU/ml of E. miricola, 100.000 
CFU/ml of Pseudomonas aeruginosa, 100 CFU/ml of Candida and 100 CFU/ml of viridans 
streptococci. The young patient was under long-term treatment with nitrofurantoin. 
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The aim of this study was to characterize the BlaB-15 enzyme and to evaluate its contribution to 
resistance phenotype. E. miricola strain SW-2 was identified by using MALDI TOF MS system 
(Bruker Daltonik, Germany). Antimicrobial susceptibility test was performed by microdilution in 
cation-adjusted Mueller–Hinton broth (BBL, Becton Dickinson) using Sensititre ESB1F plates and 
GNX2F (TREK Diagnostic Systems, West Sussex, UK). Susceptibility results were interpreted 
according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
criteria set for Pseudomonas spp. (Eucast, 2015). As shown in Table 1, E. miricola SW-2 exhibits 
high MIC values for a large panel of antimicrobials including all cephalosporins, aztreonam, 
carbapenems, aminoglycosides, fluoroquinolones and polymyxins. 
Genomic DNA of E. miricola SW-2 was extracted according to standard procedure (Sambrook et 
al., 1989). The presence of large plasmid was also ascertained using Kado method (Kado and Liu, 
1981), but no plasmids bands were detected observed in E. miricola SW2. PCR screening was 
performed using specific primers to identify blaKPC, blaVIM, blaIMP, blaNDM-1, blaTEM, blaSHV, blaCTX-
M determinants as previously reported (Perilli et al., 2013); the presence of blaB and blaGOB genes 
was explored by using the following primers: BlaB-for 
5’GGGGCATATGTTGAAAAGATTAAAAGGATTATT, BlaB-rev 
5’GGGGGATCCTTAATTTGAAGCCTTTTGTTTTGTTG, BlaGOB-for 
5’ATGAGAAATTTTGCTACACTG and BlaGOB-rev 5’TCGAACTGACTTGCATG. To 
investigate the presence of mobile genetic elements, PCR experiments were performed with  
specific primers for intI1, intI2 and intI3 genes and variable region. Integrons of class 1, 2,3 and 
serin-β-lactamases were not found in chromosomal DNA of E. miricola. Moreover, tTwo amplicons 
of 747 bp and 825 bp were amplified by BlaB-for/BlaB-rev and BlaGOB-for/BlaGOB-rev primers, 
respsctively. The purified fragments were sequenced on both strands using a BigDye Sequencing 
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Reaction Kit and an ABI PRISM1 310 Capillary Automated Sequencer (Life Technologies, Monza, 
Italy).  
Nucleotide sequences revealed that amplicons of 747 bp and 825 bp encoded for blaB-like and 
blaGOB-like metallo-β-lactamases (MBLs), respectively. The amplicon of 747 bp, encoding for an 
open reading frame of 249 amino acids, had more than 90% amino acid identity with BlaB variant. 
However, some changes in the amino acid sequence make the present BlaB enzyme as new variant, 
named BlaB-15 (GenBank accession number KR054962). The figure 1 illustrates the comparison of 
BlaB-15 with other BlaB-variants with which our enzyme shows an higher similarity score (BlaB, 
BlaB-5, BlaB-7 and BlaB-8). For instance, with respect to BlaB prototype, BlaB-15 shows 18 
different amino acids in the mature enzyme and 8 different residues in signal peptide. The gene 
blaGOB-like of 825 bp encodes for a protein of 280 amino acids that lacks the C-terminal portion. 
In figure 2 our GOB enzyme was compared with GOB-1 and GOB-7 variants. Compared to GOB-
1, GOB-like shows 19 different residues in the mature enzyme. Despite of GOB-7, the enzyme 
produced by E. miricola SW2 showed an unusual residue of valine at position 258 (BBL B3 
classification). In knownAmong GOB MBLs (http://www.ncbi.nlm.nih.gov), the position 258 is 
usually occupied by a leucine (GOB-1, -3, -4, -5, -6, -12, -13) or isoleucine (GOB-8, -9, -10, -18) 
residues (Bellais et al., 2000). However, the blaGOB-like gene found in E. miricola was not cloned 
and GOB-like enzyme was not characterized because it lacks in C-terminal region. 
The blaB-15 gene was cloned into pET-24(a) vector using NdeI and BamHI restriction sites to 
obtain the recombinant plasmid pET-BlaB-15 that was inserted by transformation in E. coli 
BL21(DE3) competent cells. The authenticity of recombinant plasmid was verified by DNA 
sequencing. The contribution of BlaB-15 to resistance phenotype was investigated versus a large 
panel of β-lactams by Minimal Inhibitory Concentration (MIC) experiments using E. coli 
BL21(DE3)/pET-BlaB-15. The antimicrobial susceptibility test was performed by conventional 
Formatted: Font: Italic
Formatted: Font: Italic
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microdilution broth procedure, using a bacterial inoculum of 5 x 10
5
 CFU/ml as recommended by 
CLSI (CLSI, 2006). As shown in table 1, BlaB-15 confers resistance to penicillins-β-lactamase 
/inhibitors combinations, cefotaxime, cefoxitin and carbapenems. Comparing MIC values with that 
reported by BlaB prototype (Bellais et al., 2000), BlaB-15 seems to confer a broader resistance 
phenotype againsthave a more large phenotype spectrum versus cephalosporins. 
In this study, we described the simultaneously presence in E. miricola of BlaB-15, a new BlaB 
variant belonging to subclass B1 MBL, and GOB-7-like enzyme belonging to subclass B3 MBL. To 
date, BlaB and GOB MBLs were mainly found in E. menungosepticum (Bellais et al., 2000). To our 
knowledge, this is the first finding of metallo-β-lactamases in E. miricola clinical strains. 
Additionally, the 2-year old baby was also colonized by an ESBL-producing K. pneumoniae. In 
fact, this strain was also investigated (data not shown) and a CTX-M-15 enzyme was found in the 
chromosomal DNA of K. pneumoniae. The co-colonization/infection of a patient with different 
strains producing several β-lactamases makes difficult the infectioncomplicates treatment.  
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 Legend to the figures  
Figure 1 
The MBL BlaB-15 amino acid sequence (GenBank accession number KR054962) was 
compared with BlaB prototype (GenBank accession number O08498), BlaB-5 (GenBank 
accession number Q9KJA9), BlaB-7 (GenBank accession number Q9KJA8) and BlaB-8 
(GenBank accession number Q9KJA7). Dashed lines indicate identical amino acid. The residues 
of BlaB-5, BlaB-7, BlaB-8 and BlaB-14 that differs from BlaB are also indicated. Arrow 
indicate the first residue of N-terminal region. In bold is indicated the sequence of BlaB-15 
enzyme found in E. miricola (this study). The catalytic residues including Zn1 ligand (H116, 
H118, H196) and Zn2 ligand (D120, C221, H263) are in bold underlined. 
 
Figure 2 
The GOB-like was compared with GOB-1 (AF090141) and GOB-7 (AF189297). Dashed lines 
indicate identical amino acids. In bold is indicated the sequence of GOB-like enzyme found in 
E. miricola (this study). The residues of GOB-7 and GOB-like that differs from GOB-1 are also 
indicated.The box shows the unique different residue between GOB-7 and GOB-like.  
 
